Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 May;73(10):1183–1186. doi: 10.1038/bjc.1996.228

Inhibition of angiogenesis and murine tumour growth by laminarin sulphate.

R Hoffman 1, D H Paper 1, J Donaldson 1, H Vogl 1
PMCID: PMC2074520  PMID: 8630276

Abstract

LAM S5 is a polysulphated derivative of the glucan laminarian that inhibits basic fibroblast growth factor (bFGF) binding and the bFGF-stimulated proliferation of fetal bovine heart endothelial (FBHE) cells. This report demonstrates that LAM S5 has anti-angiogenic activity, as shown by inhibition of tubule formation by endothelial cells cultured on Matrigel and inhibition of vascularisation of the chick chorioallantoic membrane. In addition, LAM S5 caused a tumour growth delay of the murine RIF-1 tumour of 2.6 days (P = 0.01).

Full text

PDF
1183

Images in this article

1184Figure 2
on p.1184

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ades E. W., Candal F. J., Swerlick R. A., George V. G., Summers S., Bosse D. C., Lawley T. J. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. 1992 Dec;99(6):683–690. doi: 10.1111/1523-1747.ep12613748. [DOI] [PubMed] [Google Scholar]
  2. Alban S., Kraus J., Franz G. Synthesis of laminarin sulfates with anticoagulant activity. Arzneimittelforschung. 1992 Aug;42(8):1005–1008. [PubMed] [Google Scholar]
  3. Candal F. J., Bosse D. C., Vogler W. R., Ades E. W. Inhibition of induced angiogenesis in a human microvascular endothelial cell line by ET-18-OCH3. Cancer Chemother Pharmacol. 1994;34(2):175–178. doi: 10.1007/BF00685937. [DOI] [PubMed] [Google Scholar]
  4. Casu B., Gennaro U. A conductimetric method for the determination of sulphate and carboxyl groups in heparin and other mucopolysaccharides. Carbohydr Res. 1975 Jan;39(1):168–176. doi: 10.1016/s0008-6215(00)82654-3. [DOI] [PubMed] [Google Scholar]
  5. Crum R., Szabo S., Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985 Dec 20;230(4732):1375–1378. doi: 10.1126/science.2416056. [DOI] [PubMed] [Google Scholar]
  6. Folkman J., Klagsbrun M. Angiogenic factors. Science. 1987 Jan 23;235(4787):442–447. doi: 10.1126/science.2432664. [DOI] [PubMed] [Google Scholar]
  7. Folkman J., Langer R., Linhardt R. J., Haudenschild C., Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science. 1983 Aug 19;221(4612):719–725. doi: 10.1126/science.6192498. [DOI] [PubMed] [Google Scholar]
  8. Folkman J. Tumor angiogenesis. Adv Cancer Res. 1985;43:175–203. doi: 10.1016/s0065-230x(08)60946-x. [DOI] [PubMed] [Google Scholar]
  9. Hoffman R., Burns W. W., 3rd, Paper D. H. Selective inhibition of cell proliferation and DNA synthesis by the polysulphated carbohydrate l-carrageenan. Cancer Chemother Pharmacol. 1995;36(4):325–334. doi: 10.1007/BF00689050. [DOI] [PubMed] [Google Scholar]
  10. Hoffman R., Paper D. H., Donaldson J., Alban S., Franz G. Characterisation of a laminarin sulphate which inhibits basic fibroblast growth factor binding and endothelial cell proliferation. J Cell Sci. 1995 Nov;108(Pt 11):3591–3598. doi: 10.1242/jcs.108.11.3591. [DOI] [PubMed] [Google Scholar]
  11. Honess D. J., Bleehen N. M. Thermochemotherapy with cis-platinum, CCNU, BCNU, chlorambucil and melphalan on murine marrow and two tumours: therapeutic gain for melphalan only. Br J Radiol. 1985 Jan;58(685):63–72. doi: 10.1259/0007-1285-58-685-63. [DOI] [PubMed] [Google Scholar]
  12. Jakobson A. M., Hahnenberger R., Magnusson A. A simple method for shell-less cultivation of chick embryos. Pharmacol Toxicol. 1989 Feb;64(2):193–195. doi: 10.1111/j.1600-0773.1989.tb00629.x. [DOI] [PubMed] [Google Scholar]
  13. Murata J., Saiki I., Makabe T., Tsuta Y., Tokura S., Azuma I. Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res. 1991 Jan 1;51(1):22–26. [PubMed] [Google Scholar]
  14. Nguyen M., Watanabe H., Budson A. E., Richie J. P., Hayes D. F., Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994 Mar 2;86(5):356–361. doi: 10.1093/jnci/86.5.356. [DOI] [PubMed] [Google Scholar]
  15. Penhaligon M., Camplejohn R. S. Combination heparin plus cortisone treatment of two transplanted tumors in C3H/He mice. J Natl Cancer Inst. 1985 Apr;74(4):869–873. [PubMed] [Google Scholar]
  16. Pesenti E., Sola F., Mongelli N., Grandi M., Spreafico F. Suramin prevents neovascularisation and tumour growth through blocking of basic fibroblast growth factor activity. Br J Cancer. 1992 Aug;66(2):367–372. doi: 10.1038/bjc.1992.272. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pluda J. M., Shay L. E., Foli A., Tannenbaum S., Cohen P. J., Goldspiel B. R., Adamo D., Cooper M. R., Broder S., Yarchoan R. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst. 1993 Oct 6;85(19):1585–1592. doi: 10.1093/jnci/85.19.1585. [DOI] [PubMed] [Google Scholar]
  18. Scott P. A., Harris A. L. Current approaches to targeting cancer using antiangiogenesis therapies. Cancer Treat Rev. 1994 Oct;20(4):393–412. doi: 10.1016/0305-7372(94)90020-5. [DOI] [PubMed] [Google Scholar]
  19. Tanaka N. G., Sakamoto N., Inoue K., Korenaga H., Kadoya S., Ogawa H., Osada Y. Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without a steroid. Cancer Res. 1989 Dec 1;49(23):6727–6730. [PubMed] [Google Scholar]
  20. Teicher B. A., Sotomayor E. A., Huang Z. D. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res. 1992 Dec 1;52(23):6702–6704. [PubMed] [Google Scholar]
  21. Thorpe P. E., Derbyshire E. J., Andrade S. P., Press N., Knowles P. P., King S., Watson G. J., Yang Y. C., Rao-Betté M. Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res. 1993 Jul 1;53(13):3000–3007. [PubMed] [Google Scholar]
  22. Twentyman P. R., Brown J. M., Gray J. W., Franko A. J., Scoles M. A., Kallman R. F. A new mouse tumor model system (RIF-1) for comparison of end-point studies. J Natl Cancer Inst. 1980 Mar;64(3):595–604. [PubMed] [Google Scholar]
  23. Yamanaka Y., Friess H., Buchler M., Beger H. G., Uchida E., Onda M., Kobrin M. S., Korc M. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 1993 Nov 1;53(21):5289–5296. [PubMed] [Google Scholar]
  24. Zugmaier G., Lippman M. E., Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst. 1992 Nov 18;84(22):1716–1724. doi: 10.1093/jnci/84.22.1716. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES